Krebs Biochemicals responded to an NSE query regarding significant stock price movement on April 8, 2026.
The company clarified no undisclosed material events under SEBI LODR Regulation 30 affected the price.
Company Secretary Rakesh Kalbate affirmed ongoing compliance with all SEBI disclosure requirements.